• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cessatech

19.60 DKK

-2.97 %

Less than 1K followers

CESSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.97 %
+7.69 %
+9.25 %
+9.99 %
+22.81 %
+75.94 %
+934.30 %
+25.08 %
+81.74 %

Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children, focused on high-impact unmet needs in acute and emergency care. The company focuses on specialty products designed for use in clinical settings and advances its programs through a partnership-based development model. Founded in 2020, Cessatech is headquartered in Denmark and led by a team with experience across drug development and commercialization.

Read more
Market cap
364.1M DKK
Turnover
162.84K DKK
Revenue
5.72M
EBIT %
-261.71 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
28.8
2026

Interim report Q2'26

26.11
2026

Interim report Q3'26

All
Research
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release12.06.2026, 13.30

Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children

Cessatech
Regulatory press release28.05.2026, 08.30

Cessatech: First Quarter Report Q1-2026

Cessatech
Regulatory press release30.03.2026, 11.45

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release13.03.2026, 08.30

Cessatech convenes its Annual General Meeting

Cessatech
Regulatory press release27.02.2026, 08.30

Cessatech A/S Announces Financial Results for the Full Year 2025

Cessatech
Regulatory press release02.02.2026, 08.00

Cessatech: Welcome to the first quarter of 2026

Cessatech
Regulatory press release13.11.2025, 08.30

Cessatech: Third Quarter Report Q3-2025

Cessatech
Regulatory press release31.10.2025, 13.00

Cessatech: CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children

Cessatech
Regulatory press release21.08.2025, 08.30

Cessatech: Second Quarter Report Q2-2025

Cessatech
Regulatory press release14.08.2025, 18.00

Cessatech: The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children

Cessatech
Press release27.06.2025, 13.31

Cessatech Q&A - June company presentation

Cessatech
Regulatory press release19.06.2025, 13.30

Cessatech strengthens Executive Management with the promotion of Martin Juhl

Cessatech
Regulatory press release11.06.2025, 14.15

Cessatech announce completion of the directed issue of shares

Cessatech
Regulatory press release28.05.2025, 22.30

Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch

Cessatech
Regulatory press release28.05.2025, 17.30

Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch

Cessatech
Regulatory press release28.05.2025, 17.15

Cessatech announces positive top-line results from its final CT001 Study 0202

Cessatech
Regulatory press release15.05.2025, 08.30

Cessatech: First Quarter Report Q1-2025

Cessatech
Regulatory press release30.04.2025, 15.45

Cessatech announces that recruitment has completed in the Paediatric Study 0202, and now the EMA submission process can be initiated for CT001

Cessatech
Regulatory press release28.03.2025, 11.30

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech
Regulatory press release12.03.2025, 08.30

Cessatech: Annual General Meeting - 28 March 2025

Cessatech